The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from ...

In advance of this week's CDC vaccine advisory meeting, HHS Secretary Robert F. Kennedy Jr. restacked the committee, claiming ...

Exemptions to new export control policies have allowed companies to ship patients’ biological materials to foreign ...

Analysts at William Blair say dapiglutide’s 11.6% weight reduction at 28 weeks could still be better, given that Zealand’s ...

Harliku is the only FDA-approved drug for alkaptonuria, a rare condition characterized by skin discoloration, arthritis and ...

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

California’s life sciences jobs led the nation last year, according to a new California Life Sciences (CLS) report. However, ...

Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from ...

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug ...

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

The U.K.-based biotech is set to enter mid-stage studies for its depression drug this year, while two other GABAA modulators ...